Clinical Trial: FT836 CAR T-cell Therapy in Combination With Daratumumab in Patients With Relapsed and/or Refractory Multiple Myeloma

U.S., Oct. 28 -- ClinicalTrials.gov registry received information related to the study (NCT07221032) titled 'FT836 CAR T-cell Therapy in Combination With Daratumumab in Patients With Relapsed and/or Refractory Multiple Myeloma' on Oct. 23.

Brief Summary: This is a phase I, interventional, single-arm, open-label, dose-finding treatment study designed to evaluate the safety and preliminary efficacy of FT836 in combination with daratumumab in adult patients with relapsed and/or refractory myeloma who have failed prior therapies.

Study Start Date: March, 2026

Study Type: INTERVENTIONAL

Condition: Relapse Multiple Myeloma Refractory Multiple Myeloma

Intervention: BIOLOGICAL: FT836 CAR T cells (1 x 10^8 cells per dose)

FT836 CAR T cells w...